All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Shanghai Henlius Biotech Inc. signed an exclusive licensing deal with Organon LLC under which Organon will in-license rights for two of Henlius’ internally developed biosimilar candidates for global commercialization, excluding China, Hong Kong, Macau and Taiwan.
Futura Medical plc has signed an exclusive licensing agreement with over the counter (OTC) distributor Cooper Consumer Health SAS to commercialize its topical, gel-based erectile dysfunction (ED) treatment Med3000, in the U.K. and Europe. Under the terms of the agreement, Cooper will pay an undisclosed price to Futura to manufacture and supply the product for five years, in compliance with EU competition law.
In a deal potentially worth more than $1.4 billion, Sichuan Kelun Pharmaceutical Co. Ltd. has out-licensed a large molecule drug in cancer to Merck & Co. Inc. for development and commercialization outside mainland China, Hong Kong, Macao, and Taiwan.